Twelve cattle with body wts ranging from 100 to 250 kg were treated using various doses and routes for four days with an E. coli derived alpha-hybrid interferon. The lowest parenteral doses (104 units per kg body wt) and the orally administered interferon did not lead to any disturbances, whereas the higher dosages led to marked changes in body temperature, pulse and respiration rates. Animals with the highest dose (108 units per kg body wt) became extremely distressed. The blood picture showed distinct changes, with very low leukocyte counts during treatment, which took weeks to recover. It is suggested that the dosages that did not lead to clinical symptoms are best suited for prophylactic or therapeutic purposes.
INTRODUCTION
After detection and first application of interferon (IFN) an IFN-rush started. IFN was almost considered as a panacea. Viral agents were the initiators that stimulated the various cells to produce IFN. In cattle the virus inducing the highest titers in mucous membranes of the respiratory and genital tracts was BHVI [1] , and a highly passaged avirulent strain of BHV1 [2] was for many years successfully used as a paramunity inducer to minimize the effects of crowding disease and treating bovine vaginitis [3] . These findings were later confirmed and it was shown that a ts-mutant of BHV1 also induces IFN production [4] . Differences in IFN induction in the respiratory tract of calves by three different parainfluenza-3-vaccines were described later [5] . IFN activity in the intestinal tract induced by rotavirus was also demonstrated 240 Otto Christian Straub [6] . Subsequently various synthetic, cell culture or bacteria derived alpha-IFNs were developed and first tested in ritro [7 11 ] with positive results. However, when the IFNs were tested in t, ivo different results were reported. A distinct protective effect was not achieved with transmissible gastroenteritis virus in newborn pigs [10] and also not with paranfluenza-3-virus in cattle [12] . Positive results were obtained in treating cattle prophylactically against BHVI [13] , bovine virus diarrhoea virus disease [14] and vaccinia virus infection [15] and for therapeutic reasons in rota and corona virus infections [16] . An effect on the course of a foot-and-mouth disease virus infection was also described [2] .
The object of this study was to examine the effects of different doses and modes of administration of an E. coli derived alpha-hybrid IFN which had been tested previously in tissue cultures and orally in calves suffering from digestive tract disorders [16] .
MATERIAL AND METHODS

A lpha-hybrid-lFN
The alpha-hybrid-IFN (ahIFN) was an E. coli derived purified, antibody free, slightly modified lymphoblastoid interferon with a specific activity of 3 x 108 units per ml, developed and provided by Hoechst AG, Frankfurt.
Animals
Twelve cattle with body weights ranging from 100 to 250 kg were parenterally or orally treated with various doses of ahlFN as summarized in Table 1 .
Clinical parameters
The white blood cell picture of all animals was determined before administration of ahIFN, together with body temperature, pulse and respiration rates. They were repeated immediately after the administrations and at hourly intervals, in general until 9 h later. The white blood cell count was also determined at intervals indicated in Tables 2 and 3 .
RESU LTS
Body temperature
After the intravenous administration there was no increase in animals with the low dose (Nos. 401 and 402, Table 1 ), but the higher doses produced a distinct elevation, with the maximum being reached between the 3rd and 6th hour (40.8'C). Following consecutive treatments, the increases were less marked. Only one animal (No. 435, Table 1 ) reached 40.8C during the 5th hour. No difference was observed between i.v., i.m. and s.c. administrations. Orally administered ahIFN did not produce any changes.
Pulse rate
A marked rise was only observed in those animals which received the highest dose (Nos. 435 and 436, Table 1 ) coinciding with the rise in temperature. The same response occurred on the following days with no reaction in the animals treated orally.
Respiration rate
Only the lowest dose and the orally treated animals failed to exhibit a distinct rise, but all the others reacted with a marked increase. Animal No. 427 started, for example, with a rate of 32/min and reached 106 after 2 h and No. 436 started with a rate of 30/min which Alpha-hybrid interferon Tables 2 and 3 .
Differential WBC counts. There was no obvious effect in the majority of animals. An initial reduction in lymphocytes was followed by a reduction in neutrophils. A similar picture was observed in the weeks following administration. A summary of the changes is shown in
Other clinical signs
These were observed in the 2 animals (Nos. 435 and 436, Table 1 ), which received the highest dose. In summary, No. 435, increased serious nasal discharge 3 h after the first injection, still present on day 2, but with laboured breathing and anorexia 2 h later. Increased salivation 1 h after the third treatment. Animal No. 436, trembling and cough L  403  1350  3888  473  3612  507  3354  1034  3525  874  2698  419  3422  7906  1482  5694  1216  5472  2032  8763  1404  6240  427  1458  6561  5328  5772  5328  5550  5512  5088  4578  6213  429  1275  3774  1098  4941  1890  3510  234  1548  2772  4697  435  1586  4392  756  4644  2035  3465  1950  5100  1827  4284  436  1530  6885  594  5940  2716  6984  2064  6536  1620  6399 after l h and a foamy nasal discharge after 2 h; no other signs were observed after the other injections.
DISCUSSION
The oral administration of 1 2 × 106 or parenteral injection of 104 units ahIFN/kg body wt did not lead to any disturbances. Hofmann et al. [16] used approximately the same dose for the treatment of digestive disorders in calves. It seems most likely therefore that the positive results can be attributed to the treatment, since this could substantiate the efficacy of ahIFN treatment in vitro and in vivo with rota-and coronaviruses. However, higher doses certainly do more harm than good, and not only for short periods of time as judged by the clinical signs, but for long periods of time, as is evident from the changes in the white blood picture. The route of parenteral administration does not seem to be relevant. The same is obviously true for the body weight resp. age. The results are in general agreement with those obtained by Gitlespie and coworkers [17] .
It is not unexpected that IFN administration does not influence PI3-virus infections [12] , as PI3-virus induces IFN activity [5] . The same is true for BHVI [1] . Therefore, there is no justification to administer IFN prior to BHV1 exposure [13] . The results are encouraging concerning BVDV infections [14] . If IFN acts as an immunostimulant [13] , it could be used to improve the immune response, especially following the vaccination with inactivated BVDV vaccines.
